Abstract
The discovery that N-acylethanolamines, such as oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), acting as endogenous ligands of alpha-type peroxisome proliferator-activated receptors (PPARα), block nicotineinduced excitation of dopamine neurons revealed their role as important endogenous negative modulators of nicotinic receptors containing β2 subunits (denoted β2*-nAChRs) on dopamine neurons, which are key to the brain reward system.
Using mass-spectrometry data analysis from rodent brain slices containing the midbrain, we characterized the effects induced by modulation of PPARα on PEA and OEA levels. PEA and OEA constitutive levels in the midbrain are higher than endocannabinoids (e.g. anandamide, 2-arachidonoylglycerol), and depend upon excessive input drive and the metabolic state of the cells. Accordingly, OEA and PEA synthesis is affected when adding low concentrations of fatty acids (endogenous PPARα ligands), most likely through activation of PPARα. Indeed, PPARα activation increases PEA and OEA levels, which may further sustain PPARα activity. Given this, it is likely that these molecules dynamically affect dopamine function and excitability, as well as their dependent behaviour. Consequently, N-acylethanolamines may confer less vulnerability towards disruption of dynamic balance of dopamine-acetylcholine systems through PPARα activation. Finally, using pharmacological and/or nutritional strategies which target PPARα might represent a promising therapeutic approach to prevent disorders often related to neuro-inflammation, stress and abnormal β2*-nAChR function.
Keywords: Dopamine, endocannabinoid, fatty acid, midbrain, oleoylethanolamide, palmitoylethanolamide, peroxisomeproliferator- activated receptors
CNS & Neurological Disorders - Drug Targets
Title:Physiological Role of Peroxisome Proliferator-Activated Receptors Type Alpha on Dopamine Systems
Volume: 12 Issue: 1
Author(s): Miriam Melis, Gianfranca Carta, Marco Pistis and Sebastiano Banni
Affiliation:
Keywords: Dopamine, endocannabinoid, fatty acid, midbrain, oleoylethanolamide, palmitoylethanolamide, peroxisomeproliferator- activated receptors
Abstract: The discovery that N-acylethanolamines, such as oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), acting as endogenous ligands of alpha-type peroxisome proliferator-activated receptors (PPARα), block nicotineinduced excitation of dopamine neurons revealed their role as important endogenous negative modulators of nicotinic receptors containing β2 subunits (denoted β2*-nAChRs) on dopamine neurons, which are key to the brain reward system.
Using mass-spectrometry data analysis from rodent brain slices containing the midbrain, we characterized the effects induced by modulation of PPARα on PEA and OEA levels. PEA and OEA constitutive levels in the midbrain are higher than endocannabinoids (e.g. anandamide, 2-arachidonoylglycerol), and depend upon excessive input drive and the metabolic state of the cells. Accordingly, OEA and PEA synthesis is affected when adding low concentrations of fatty acids (endogenous PPARα ligands), most likely through activation of PPARα. Indeed, PPARα activation increases PEA and OEA levels, which may further sustain PPARα activity. Given this, it is likely that these molecules dynamically affect dopamine function and excitability, as well as their dependent behaviour. Consequently, N-acylethanolamines may confer less vulnerability towards disruption of dynamic balance of dopamine-acetylcholine systems through PPARα activation. Finally, using pharmacological and/or nutritional strategies which target PPARα might represent a promising therapeutic approach to prevent disorders often related to neuro-inflammation, stress and abnormal β2*-nAChR function.
Export Options
About this article
Cite this article as:
Melis Miriam, Carta Gianfranca, Pistis Marco and Banni Sebastiano, Physiological Role of Peroxisome Proliferator-Activated Receptors Type Alpha on Dopamine Systems, CNS & Neurological Disorders - Drug Targets 2013; 12 (1) . https://dx.doi.org/10.2174/1871527311312010012
DOI https://dx.doi.org/10.2174/1871527311312010012 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mitochondria, Mitochondrial DNA and Alzheimers Disease. What Comes First?
Current Alzheimer Research ATP Synthesis Revisited: New Avenues for the Management of Mitochondrial Diseases
Current Pharmaceutical Design Helicobacter pylori Current Chemotherapy and New Targets for Drug Design
Current Pharmaceutical Design Minimizing AED Adverse Effects: Improving Quality of Life in the Interictal State in Epilepsy Care
Current Neuropharmacology Editorial Review (Thematic Issue: An Update on Central Sensitivity Syndromes and the Issues of Nosology and Psychobiology)
Current Rheumatology Reviews How can Proteomics Reach Cancer Biomarkers?
Current Proteomics Vascular Changes of the Retina and Choroid in Systemic Lupus Erythematosus: Pathology and Pathogenesis
Current Neurovascular Research Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery The Ubiquitous Choline Transporter SLC44A1
Central Nervous System Agents in Medicinal Chemistry Non-Pharmacologic Treatment Options in Rheumatologic Disease
Current Rheumatology Reviews Cutaneous Markers of HIV Infection and Progression
Current HIV Research Expanding our Understanding of Polyglutamine Disease Through Transgenic Mice
Current Genomics Psychotic (Delusional) Major Depression in the Elderly: A Review
Current Psychiatry Reviews Mesenchymal Stem Cells in Cartilage Regeneration
Current Stem Cell Research & Therapy Promiscuous Seven Transmembrane Receptors Sensing L-α-amino Acids
Current Pharmaceutical Design Neurodegenerative Disorders and the Current State, Pathophysiology, and Management of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Prevalence, Severity and Characteristics of Tardive Dyskinesia Among Schizophrenia Patients in an Israeli Psychiatric Center
Current Psychopharmacology Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson’s Disease Associated Mutations
Current Protein & Peptide Science Voltage-Gated Sodium Channels in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson’s Disease
Current Genomics